Drugs for Chronic Obstructive Pulmonary Disorder Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

1 RESEARCH SCOPE

1.1 Research Product Definition

1.2 Research Segmentation

1.2.1 Product Type

1.2.2 Main product Type of Major Players

1.3 Demand Overview

1.4 Research Methodology

2 GLOBAL DRUGS FOR CHRONIC OBSTRUCTIVE PULMONARY DISORDER INDUSTRY

2.1 Summary about Drugs for Chronic Obstructive Pulmonary Disorder Industry

2.2 Drugs for Chronic Obstructive Pulmonary Disorder Market Trends

2.2.1 Drugs for Chronic Obstructive Pulmonary Disorder Production & Consumption Trends

2.2.2 Drugs for Chronic Obstructive Pulmonary Disorder Demand Structure Trends

2.3 Drugs for Chronic Obstructive Pulmonary Disorder Cost & Price

3 MARKET DYNAMICS

3.1 Manufacturing & Purchasing Behavior in 2020

3.2 Market Development under the Impact of COVID-19

3.2.1 Drivers

3.2.2 Restraints

3.2.3 Opportunity

3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

4.1 Region Segmentation (2017 to 2021f)

4.1.1 North America (U.S., Canada and Mexico)

4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)

4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)

4.1.4 South America (Brazil,, Argentina, Rest of Latin America)

4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)

4.2 Product Type Segmentation (2017 to 2021f)

4.2.1 Short-Acting Bronchodilators

4.2.2 Corticosteroids

4.2.3 Methylxanthines

4.2.4 Long-Acting Bronchodilators

4.2.5 Phosphodiesterase-4 Inhibitors

4.3 Consumption Segmentation (2017 to 2021f)

4.3.1 GOLD 1? FEV1 ? 80%

4.3.2 GOLD 2? 50% ? FEV1 < 80%

4.3.3 GOLD 3? 30% ? FEV1 < 50%

4.3.4 GOLD 4? FEV1 < 30%

5 NORTH AMERICA MARKET SEGMENT

5.1 Region Segmentation (2017 to 2021f)

5.1.1 U.S.

5.1.2 Canada

5.1.3 Mexico

5.2 Product Type Segmentation (2017 to 2021f)

5.2.1 Short-Acting Bronchodilators

5.2.2 Corticosteroids

5.2.3 Methylxanthines

5.2.4 Long-Acting Bronchodilators

5.2.5 Phosphodiesterase-4 Inhibitors

5.3 Consumption Segmentation (2017 to 2021f)

5.3.1 GOLD 1? FEV1 ? 80%

5.3.2 GOLD 2? 50% ? FEV1 < 80%

5.3.3 GOLD 3? 30% ? FEV1 < 50%

5.3.4 GOLD 4? FEV1 < 30%

5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

6.1 Region Segmentation (2017 to 2021f)

6.1.1 Germany

6.1.2 UK

6.1.3 France

6.1.4 Italy

6.1.5 Rest of Europe

6.2 Product Type Segmentation (2017 to 2021f)

6.2.1 Short-Acting Bronchodilators

6.2.2 Corticosteroids

6.2.3 Methylxanthines

6.2.4 Long-Acting Bronchodilators

6.2.5 Phosphodiesterase-4 Inhibitors

6.3 Consumption Segmentation (2017 to 2021f)

6.3.1 GOLD 1? FEV1 ? 80%

6.3.2 GOLD 2? 50% ? FEV1 < 80%

6.3.3 GOLD 3? 30% ? FEV1 < 50%

6.3.4 GOLD 4? FEV1 < 30%

6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

7.1 Region Segmentation (2017 to 2021f)

7.1.1 China

7.1.2 India

7.1.3 Japan

7.1.4 South Korea

7.1.5 Southeast Asia

7.1.6 Australia

7.1.7 Rest of Asia Pacific

7.2 Product Type Segmentation (2017 to 2021f)

7.2.1 Short-Acting Bronchodilators

7.2.2 Corticosteroids

7.2.3 Methylxanthines

7.2.4 Long-Acting Bronchodilators

7.2.5 Phosphodiesterase-4 Inhibitors

7.3 Consumption Segmentation (2017 to 2021f)

7.3.1 GOLD 1? FEV1 ? 80%

7.3.2 GOLD 2? 50% ? FEV1 < 80%

7.3.3 GOLD 3? 30% ? FEV1 < 50%

7.3.4 GOLD 4? FEV1 < 30%

7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

8.1 Region Segmentation (2017 to 2021f)

8.1.1 Brazil

8.1.2 Argentina

8.1.3 Rest of Latin America

8.2 Product Type Segmentation (2017 to 2021f)

8.2.1 Short-Acting Bronchodilators

8.2.2 Corticosteroids

8.2.3 Methylxanthines

8.2.4 Long-Acting Bronchodilators

8.2.5 Phosphodiesterase-4 Inhibitors

8.3 Consumption Segmentation (2017 to 2021f)

8.3.1 GOLD 1? FEV1 ? 80%

8.3.2 GOLD 2? 50% ? FEV1 < 80%

8.3.3 GOLD 3? 30% ? FEV1 < 50%

8.3.4 GOLD 4? FEV1 < 30%

8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

9.1 Region Segmentation (2017 to 2021f)

9.1.1 GCC

9.1.2 North Africa

9.1.3 South Africa

9.1.4 Rest of Middle East and Africa

9.2 Product Type Segmentation (2017 to 2021f)

9.2.1 Short-Acting Bronchodilators

9.2.2 Corticosteroids

9.2.3 Methylxanthines

9.2.4 Long-Acting Bronchodilators

9.2.5 Phosphodiesterase-4 Inhibitors

9.3 Consumption Segmentation (2017 to 2021f)

9.3.1 GOLD 1? FEV1 ? 80%

9.3.2 GOLD 2? 50% ? FEV1 < 80%

9.3.3 GOLD 3? 30% ? FEV1 < 50%

9.3.4 GOLD 4? FEV1 < 30%

9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

10.1 Brief Introduction of Major Players

10.1.1 AstraZeneca

10.1.2 Boehringer Ingelheim

10.1.3 GSK

10.1.4 Novartis

10.1.5 Teva Pharmaceuticals

10.1.6 Ache Laboratorios Farmaceuticos

10.1.7 Almirall

10.1.8 Aquinox Pharmaceuticals

10.1.9 Ario Pharma

10.1.10 Asmacure

10.1.11 Astellas Pharma

10.1.12 BioMarck Pharmaceuticals

10.2 Drugs for Chronic Obstructive Pulmonary Disorder Sales Date of Major Players (2017-2020e)

10.2.1 AstraZeneca

10.2.2 Boehringer Ingelheim

10.2.3 GSK

10.2.4 Novartis

10.2.5 Teva Pharmaceuticals

10.2.6 Ache Laboratorios Farmaceuticos

10.2.7 Almirall

10.2.8 Aquinox Pharmaceuticals

10.2.9 Ario Pharma

10.2.10 Asmacure

10.2.11 Astellas Pharma

10.2.12 BioMarck Pharmaceuticals

10.3 Market Distribution of Major Players

10.4 Global Competition Segmentation

11 MARKET FORECAST

11.1 Forecast by Region

11.2 Forecast by Demand

11.3 Environment Forecast

11.3.1 Impact of COVID-19

11.3.2 Geopolitics Overview

11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

1.Table Drugs for Chronic Obstructive Pulmonary Disorder Product Type Overview

2.Table Drugs for Chronic Obstructive Pulmonary Disorder Product Type Market Share List

3.Table Drugs for Chronic Obstructive Pulmonary Disorder Product Type of Major Players

4.Table Brief Introduction of AstraZeneca

5.Table Brief Introduction of Boehringer Ingelheim

6.Table Brief Introduction of GSK

7.Table Brief Introduction of Novartis

8.Table Brief Introduction of Teva Pharmaceuticals

9.Table Brief Introduction of Ache Laboratorios Farmaceuticos

10.Table Brief Introduction of Almirall

11.Table Brief Introduction of Aquinox Pharmaceuticals

12.Table Brief Introduction of Ario Pharma

13.Table Brief Introduction of Asmacure

14.Table Brief Introduction of Astellas Pharma

15.Table Brief Introduction of BioMarck Pharmaceuticals

16.Table Products & Services of AstraZeneca

17.Table Products & Services of Boehringer Ingelheim

18.Table Products & Services of GSK

19.Table Products & Services of Novartis

20.Table Products & Services of Teva Pharmaceuticals

21.Table Products & Services of Ache Laboratorios Farmaceuticos

22.Table Products & Services of Almirall

23.Table Products & Services of Aquinox Pharmaceuticals

24.Table Products & Services of Ario Pharma

25.Table Products & Services of Asmacure

26.Table Products & Services of Astellas Pharma

27.Table Products & Services of BioMarck Pharmaceuticals

28.Table Market Distribution of Major Players

29.Table Global Major Players Sales Revenue (Million USD) 2017-2020e

30.Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e

31.Table Global Drugs for Chronic Obstructive Pulmonary Disorder Market Forecast (Million USD) by Region 2021f-2026f

32.Table Global Drugs for Chronic Obstructive Pulmonary Disorder Market Forecast (Million USD) Share by Region 2021f-2026f

33.Table Global Drugs for Chronic Obstructive Pulmonary Disorder Market Forecast (Million USD) by Demand 2021f-2026f

34.Table Global Drugs for Chronic Obstructive Pulmonary Disorder Market Forecast (Million USD) Share by Demand 2021f-2026f